Equasym XR 30 mg

Equasym XR 30 mg is a modified-release capsule containing 30 mg of methylphenidate hydrochloride, primarily used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The medication is manufactured in multiple countries, including Belgium, where it is produced by UCB Pharma, a global biopharmaceutical company headquartered in Brussels. UCB Pharma specializes in neurology and immunology treatments and is the ultimate owner of the Equasym XR brand. The capsules are designed to release 30% of the methylphenidate immediately, providing an initial dose in the morning, with the remaining 70% released gradually over eight hours, covering the school day without the need for a lunchtime dose. The 30 mg capsules have a reddish-brown opaque cap imprinted with 'S544' in white and a white opaque body imprinted with '30 mg' in black. The active ingredient, methylphenidate hydrochloride, is a central nervous system stimulant that increases the activity of dopamine and norepinephrine in the brain, aiding in the control of attention and behavior in individuals with ADHD. The medication is available in various strengths, including 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, with the 30 mg capsule containing 30 mg of methylphenidate hydrochloride corresponding to 25.94 mg of methylphenidate. The other ingredients include sugar spheres (sucrose and maize starch), povidone K29 to K32, Opadry Clear YS-1-7006 (hypromellose, macrogol 400 and macrogol 8000), ethylcellulose aqueous dispersion, and dibutyl sebacate. The capsule shell consists of gelatin and titanium dioxide (E171). The 30 mg capsule also contains indigo carmine (E132) and red iron oxide (E172). The medication should be stored below 25°C and not used if the capsules are damaged. It is important to follow the prescribed dosage and consult a healthcare professional for any concerns or side effects.